Sales of Sepracor’s Xopenex down
MARLBOROUGH, Mass.--Sepracor’s Xopenex sales declined for the second quarter of 2008, the respiratory medication manufacturer reported July 29. Sales of the COPD drug were $85.4 million, compared to $103.5 million for the same period a year ago. The company said the decrease was due, in part, to Medicare’s decision last year to pay for the pricier brand-name drug at the same rate as general albuterol. Things were brighter for Sepracor’s Brovana sales, which more than doubled from $13.3 million from $5.5 million a year ago. The long-acting COPD drug was launched in April 2007.